Introduction Malignant pleural effusions are a common complication of advanced malignancy, have a poor prognosis and have a significant impact on quality of life. Treatment strategies include chest drain and pleurodesis, or insertion of an indwelling pleural catheter. Successful pleurodesis is thought to be due to the body's inflammatory response resulting in pleural symphysis. This post hoc analysis of data from the TIME 1 was conducted to address assess whether there is a correlation between the pleurodesis and a systemic inflammatory response. Methods A total of 282 patients from the TIME 1 trial had data on pleurodesis success, which was defined as no further pleural procedures for up to 3 months after pleurodesis. Patients who had undergone thoracosopy and poudrage as well as those who had undergone chest drain with pleurodesis were included. Sterile talc was used in all patients. The difference in the white cell count (WCC) and C-reactive protein (CRP) levels was calculated between the day of pleurodesis (Day 0) and Day 1. The data are normally distributed thus independent t test was used for analysis. The CRP Day 0 and 1 data were not normally distributed, and therefore were log transformed to produce a normal distribution. Results Two hundred and eighty two patients were included in the analysis with a mean age of 71 in both groups. 229 had a successful pleurodesis and 53 patients required a further pleural procedure on the ipsilateral side signifying failed pleurodesis. 193 patients had CRP levels and 220 patients had WCC levels recorded on both Day 0 and Day 1.
Patients who had a successful pleurodesis had a significantly greater rise in CRP than those who failed pleurodesis. There was no significant difference in the change in WCC between the groups. There was also no significant difference in Day 0 and Day 1 WCC or CRP levels between the two groups. Conclusions This analysis demonstrates that systemic rise in CRP as an indicator of inflammation is a better predictor of pleurodesis success than the WCC. These data support the hypothesis that higher levels of inflammation are associated with pleurodesis success.
Abstract S129 Methods 466 patients with suspected MPE, recruited to the prospective, multi-centre DIAPHRAGM study (ISRCTN10079972) in Glasgow and South Manchester, were selected. All data was recorded prospectively except CT reports, which were retrieved retrospectively from electronic records. Cases were classified into 'benign' and 'malignant' CT groups (using previously published criteria (Hallifax et al 2014, Tsim et al 2016), and asbestos-exposed and nonexposed groups. The diagnostic performance of pleural cytology was compared based on these features. Results 36/466 (8%) were excluded (non-contrast CT (n=15), non-contiguous CT (n=5), no definitive diagnosis (n=16)). In the remaining 430 cases, median age was 73 (IQR 66-80) years. 264/430 (61%) were diagnosed with MPE, of whom 107 (41%) had MPM. Median time from pleural aspiration to cytology report was 6 (4 -9) days. Median time from pleural aspiration to pleural biopsy was 20 (12 -36) days. 189/430 (44%) were asbestos-exposed. 189/430 (44%) had a 'malignant' CT report. The diagnostic performance of pleural cytology based on combinations of these features is summarised in Table 1 . In patients with MPE, the majority of patients with benign or non-diagnostic cytology had MPM (92/152 (61%)), particularly in asbestos-exposed patients (69/79 (87%)). Conclusions Pleural cytology is frequently unhelpful in patients with MPE. The sensitivity and negative predictive value of pre-LAT aspiration cytology appears particularly low in patients with CT evidence of pleural tumour and a history of asbestos exposure, reflecting a higher prevalence of MPM. A 'direct to LAT' strategy, assuming pleural chemistry and microbiology suggest a sterile exudate, may be appropriate in these cases. However, a prospective study would be required to validate such an approach.
Abstract S130 Table 1 The diagnostic performance of pleural fluid cytology in 430 patients with suspected pleural malignancy. 390/430 (91%) had pleural fluid cytology performed. Prevalence of pleural malignancy in this cohort was 61% (n=264). 37/390 (9%) had cleady benign effusions based on pleural fluid biochemistry and microbiology results and are excluded from the analyses below
Spoken sessions

A78
Thorax 2017;72(Suppl 3):A1-278
